Peter Evan Harwin
Sits on 10 boards. Overboarded · 10 public boards Last updated September 27, 2026
Time on boards
- Boards served
- 10
- Current seats
- 10
- Board service
- 21 years
- Director since
- 2023
21 years of board service in total across 10 boards, counting each seat separately. Longest: Cogent Biosciences Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Oruka Therapeutics Inc. June 2, 202599.6%
-
Spyre Therapeutics Inc. May 29, 202582.7%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 9, 2026 | Damora Therapeutics Inc. | Option exercise | +5,809,000 | — | — |
| Feb 9, 2026 | Damora Therapeutics Inc. | Option exercise | +2,904,000 | — | — |
| Dec 4, 2025 | Crescent Biopharma Inc. | Open-market purchase | +1,360,000 | $13.41 | $18,237,600 |
| Oct 7, 2025 | Zenas BioPharma Inc. | Open-market purchase | +316,219 | $19.00 | $6,008,161 |
| Sep 16, 2024 | Zenas BioPharma Inc. | Derivative conversion | +41,130 | — | — |
| Sep 16, 2024 | Zenas BioPharma Inc. | Derivative conversion | +252,890 | — | — |
| Sep 16, 2024 | Zenas BioPharma Inc. | Derivative conversion | +709,794 | — | — |
| Sep 16, 2024 | Zenas BioPharma Inc. | Derivative conversion | +301,077 | — | — |
| Sep 16, 2024 | Zenas BioPharma Inc. | Open-market purchase | +300,000 | $17.00 | $5,100,000 |
| Apr 25, 2024 | Spyre Therapeutics Inc. | Option exercise | +3,639,680 | — | — |
| Sep 29, 2023 | Dianthus Therapeutics Inc. | Open-market purchase | +24,670 | $13.63 | $336,252 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.